Syros Pharmaceuticals Current Ratio 2015-2021 | SYRS

Syros Pharmaceuticals current ratio from 2015 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Syros Pharmaceuticals Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.19B $0.03B 6.74
2021-03-31 $0.23B $0.03B 8.28
2020-12-31 $0.18B $0.03B 6.24
2020-09-30 $0.10B $0.03B 3.51
2020-06-30 $0.11B $0.02B 4.85
2020-03-31 $0.13B $0.02B 6.35
2019-12-31 $0.12B $0.02B 4.87
2019-09-30 $0.11B $0.02B 4.92
2019-06-30 $0.12B $0.02B 8.11
2019-03-31 $0.08B $0.02B 5.19
2018-12-31 $0.10B $0.02B 5.21
2018-09-30 $0.12B $0.02B 5.43
2018-06-30 $0.13B $0.02B 7.18
2018-03-31 $0.12B $0.02B 5.78
2017-12-31 $0.07B $0.01B 5.89
2017-09-30 $0.08B $0.01B 9.00
2017-06-30 $0.09B $0.01B 13.28
2017-03-31 $0.07B $0.01B 10.56
2016-12-31 $0.09B $0.01B 8.94
2016-09-30 $0.10B $0.01B 11.37
2016-06-30 $0.05B $0.01B 8.48
2016-03-31 $0.00B 0.00
2015-12-31 $0.00B 0.00
2015-09-30 $0.00B 0.00
2015-06-30 $0.00B 0.00
2014-12-31 $0.06B $0.00B 48.43
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.261B $0.015B
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company's product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76